Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04515797 · ClinicalTrials.gov registry record · Phase 4
QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT04515797: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT04515797 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04515797, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a single center study characterizing the experience of administration of 4 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.
Interventions
- DRUG Glecaprevir and Pibrentasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-05-01 |
| Est. Completion | 2023-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04515797
The ClinicalTrials.gov registry entry for NCT04515797 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glecaprevir and Pibrentasvir is the first listed.
NCT04515797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04515797 about?
NCT04515797 is a clinical study titled "QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir". This is a single center study characterizing the experience of administration of 4 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.
What is the current status of trial NCT04515797?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2021-05-01. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT04515797?
The interventions under investigation include: Glecaprevir and Pibrentasvir (DRUG).
Who is sponsoring clinical trial NCT04515797?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.